High-fidelity DNA Polymerase-Based PNA-PCR Plus Pyrosequencing: is It a Sensitive and Accurate Assay for Genotyping and Quantifying Plasma KRAS Mutations?

S. Yu,B. Liu,J. Wei,L. Xie
DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.e21006
IF: 45.3
2011-01-01
Journal of Clinical Oncology
Abstract:e21006 Background: Plasma DNA may harbor tumor-specific genetic alternations and could be used as surrogate tumor tissues for nonivasive examination of tumor-specific gene mutation. Peptide nucleic acid (PNA)-PCR is reported to be a high sensitivity method to screen KRAS mutation from plasma/serum of cancer patients. However, since DNA polymerase errors could affect the performance of PNA-PCR and most of PNA-PCR reports didn’t take this into consideration, it’s necessary to compare the mutation status between plasma and tumor tissue to evaluate the effect of DNA polymerase errors during PNA-PCR. Methods: High-fidelity DNA polymerase based PNA-PCR plus pyroquencing assay was developed and its detection limit was assessed by dilutions of the KRAS mutant DNA. Using this assay, we investigated KRAS mutations on cell-free DNA from 19 (15 pre-operations and 4 post-operations) pancreatic cancer patients. KRAS mutation status of these 19 patients was also screened on formalin-fixed paraffin-embedded (FFPE) tumor specimens and compared with results from plasma. Results: PNA-PCR plus pyrosequencing assay could detect as little as 20 pg of mutant DNA (1:5000 mutant to wild-type ratio) and could completely suppress the amplification of wild-type DNA, which enabled the quantification of mutant DNA simultaneously. Overall incidences of KRAS mutation at FFPE samples was 16 out of 19 (84.2%), and 14 corresponding plasma specimens was also found the existence of KRAS mutations. The plasma mutation type was identical to tumor tissue in 13 out of 14 subjects (92.9%) except for one subject whose plasma was gathered after operation and a serial of chemotherapy. Conclusions: High-fidelity DNA polymerase based PNA-PCR plus pyrosequencing is a sensitive, fast and accurate assay to screen plasma KRAS mutations and has potential to quantify KRAS mutant DNA in order to predict treatment response and monitor disease progression.
What problem does this paper attempt to address?